31,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
This is relevant as the number of old people (a) living alone and (b) suffering from dementia is expected to increase rapidly in the next decades. 2 key findings →
Design: longitudinal study Participants: 201 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
= 0.04). Replacing 1 serving per day of nuts and legumes for processed red meat was associated with a 19% lower risk of dementia (HR 0.81, 95% CI 0.75-0.86), 1.37 fewer years of cognitive aging (95% CI -2.49 to -0.25), and a 21% lower risk of SCD (RR 0.79, 95% CI 0.68-0.92). 4 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
From October 2018 to March 2020, 58 participants were recruited (29 per group, 95% [86%-99%]). 5 key findings →
Design: randomized controlled trial Participants: 58 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Early age at surgical menopause was associated with cognitive decline and AD neuropathology. 4 key findings →
Design: longitudinal study Participants: 1,884 Evidence: moderate
Full summary, score breakdown and related studies → Original source
This 23-year study found a U-shaped relationship between alcohol and dementia risk: people who abstained from alcohol in midlife, as well as those who drank heavily (more than 14 units, about 14 standard drinks, per week), both had a higher risk of developing dementia than people who drank moderately. 4 key findings →
Design: cohort Participants: 9,087 Evidence: moderate
Full summary, score breakdown and related studies → Original source
Among older adults with diabetes, no clear evidence was found that the incidence of dementia differed overall between patients using GLP-1RAs versus DPP4is. 4 key findings →
Design: cohort Participants: 7,254 Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this study, terminating metformin treatment was associated with increased dementia incidence. 5 key findings →
Design: cohort Participants: 41,346 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Compared with non-users, SGLT-2i, GLP-1RA, TZD and metformin were associated with the reduced risk of dementia in patients with T2D. SGLT-2i, and GLP-1RA may serve as the optimal choice to improve the cognitive prognosis in patients with T2D. 5 key findings →
Design: meta-analysis Participants: 3,462,926 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Smoking cessation was associated with a sustained lower dementia risk and slower cognitive decline, comparable to never smokers and those without short-term risk increase. 5 key findings →
Design: cohort Participants: 32,802 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
In this cohort and MR study of UK Biobank participants, cataracts were associated with increased risk of dementia, especially vascular dementia, and reduced total brain volumes. 5 key findings →
Design: cohort Participants: 304,953 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Female participants had a lower hazard of early-onset dementia compared with males (HR 0·70 [95% CI 0·61-0·80]). 4 key findings →
Design: cohort Participants: 544,442 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Metformin should continue to be used as a first line therapy for diabetes in patients at risk of developing dementia or Alzheimer's disease. 4 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Observational studies support the use of NSAIDs for prevention of AD, but RCT do not. 4 key findings →
Design: randomized controlled trial Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
High intake of total, saturated, and trans fat and cholesterol and low intake of MUFA, PUFA, n-6 PUFA, and n-3 PUFA were not associated with increased risk of dementia or its subtypes. 4 key findings →
Design: cohort study Participants: 5,395 Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Dietary patterns and some dietary components have been linked with dementia. 1 key finding →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Stroke, dementia, and hypertension are associated with late-onset epilepsy; however, the role of other vascular and lifestyle factors remains unclear. 5 key findings →
Design: cohort study Participants: 792 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Broad consensus emerged on the protective role against dementia of leisure activities. 3 key findings →
Design: systematic review Participants: 26 Evidence: high
Full summary, score breakdown and related studies → Original source Full text may need a subscription
Sample 1 included 1656 participants (mean [range] age, 58.1 [29.7-85.6] years; 903 female [54.5%]), and sample 2 included 935 participants (mean [range] age, 67.6 [60.0-85.6] years; 518 female [55.4%]). 4 key findings →
Design: cohort study Participants: 1,656 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
A total of 450 111 participants were included in the study (mean [SD] age, 51.1 [9.8] years; 70.8% women) and followed up during a median (IQR) time of 14.9 (4.1) years. 5 key findings →
Design: cohort study Participants: 111 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Of the 14 685 participants (7355 female [50%] and 7330 male [50%]; mean [SD] age, 73.8 [8.5] years) who met the inclusion criteria, 221 participants (1.5%) developed LOE during follow-up. 5 key findings →
Design: longitudinal study Participants: 713 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Metformin might correlate with a lower dementia incidence in people with T2DM. 4 key findings →
Design: meta-analysis Participants: 3,463,100 Evidence: early
Full summary, score breakdown and related studies → Original source Full text may need a subscription
For the last 17 years, an increase of mortality for patients with hip fracture and a higher mortality rate in men than in women were observed. 5 key findings →
Design: cohort study Participants: 3,992 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
At baseline, 4,463 subjects were without dementia, 836 of whom had HL. 3 key findings →
Design: cohort study Participants: 4,463 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Our study has identified not only risk factors associated with functional decline but also the interactions among these factors. 5 key findings →
Design: cohort study Evidence: moderate
Full summary, score breakdown and related studies → Original source Full text may need a subscription
These results confirm the absence of a neurocognitive risk associated with statin treatment and suggest a potential favourable role of statins. 5 key findings →
Design: meta-analysis Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled. Show only studies that are free to read
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 31,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 31,380 records, built mostly from automated pulls of Europe PMC (65.6% of the library) and OpenAlex (16.2%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,048 records (3.3% of the library) are not peer-reviewed — 973 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →
Newest studies, as a dated timeline → Atom feed Where this research is being discussed: events